Fournier’s gangrene is a necrotizing infection of the external genitalia, perineal or perianal regions and is mainly seen in males. Its main risk factors include diabetes, chronic alcoholism, HIV and other immune-compromised states. Fournier’s gangrene has an aggressive course associated with a mortality rate of 20%−30%, making early diagnosis and management very important. The Fournier Gangrene Severity Index (FGSI) has been traditionally used to predict the severity and prognosis. More recently, simplified FGSI (sFGSI) has been proposed and is helpful. However, timely diagnosis, supportive medical management and complete surgical debridement are still the cornerstones of treatment. These must be complemented with early and timely re-look debridements and appropriate reconstruction to cover soft tissue defects. This literature review aims to look at recent relevant research regards risk factors and prognostic features of Fournier’s gangrene.
Methods:
A search was conducted on Google Scholar and PubMed databases for all articles related to Fournier’s Gangrene. These included clinical reviews, case reports, case series and retrospective studies. Reports or studies which were not published in English were not reviewed. Various reconstructive techniques to cover the defects have also been revisited.
Results:
Broad-spectrum antibiotics and urgent surgical debridement are the core management principles of Fournier’s gangrene. Repeat debridement after 24 h is also recommended. Adjunctive therapies such as hyperbaric oxygen and vacuum-assisted closure are supported in most aspects of recent literature. Expectedly, there is a lack of randomised controlled studies in such emergency surgical conditions, which limits the widespread use of newer therapies to patients unresponsive to conventional management.
Conclusion:
Fournier’s gangrene is a urological emergency with a high mortality rate. The aggressive nature of the infection necessitates early recognition and immediate surgical intervention. Negative pressure dressing and occasional hyperbaric oxygen as adjuncts should be used more routinely, especially if there is a delayed response to conventional treatment or in severe infections.
HuayllaniMTCheemaASMcGuireMJ, et al. Practical review of the current management of Fournier’s gangrene. Plast Reconstr Surg Glob Open2022; 10(3): e4191.
4.
KabaySYucelMYaylakF, et al. The clinical features of Fournier’s gangrene and the predictivity of the Fournier’s gangrene Severity Index on the outcomes. Int Urol Nephrol2008; 40(4): 997–1004.
5.
IacovelliVCiprianiCSandriM, et al. The role of vacuum-assisted closure (VAC) therapy in the management of Fournier’s gangrene: a retrospective multi-institutional cohort study. World J Urol2021; 39(1): 121–128.
6.
LaorEPalmerLSToliaBM, et al. Outcome prediction in patients with Fournier’s gangrene. J Urol1995; 154(1): 89–92.
7.
CorcoranATSmaldoneMCGibbonsEP, et al. Validation of the Fournier’s gangrene severity index in a large contemporary series. J Urol2008; 180(3): 944–948.
8.
OyelowoNAhmedMLawalAT, et al. Fournier’s gangrene: presentation and predictors of mortality in Zaria, Nigeria. Ann Afr Med2021; 20(2): 105–110.
9.
LinTYOuCHTzaiTS, et al. Validation and simplification of Fournier’s gangrene severity index. Int J Urol2014; 21(7): 696–701.
10.
ClaytonMDFowlerJEJrSharifiR, et al. Causes, presentation and survival of fifty-seven patients with necrotizing fasciitis of the male genitalia. Surg Gynecol Obstet1990; 170(1): 49–55.
11.
GargGSinghVSinhaRJ, et al. Outcomes of patients with Fournier’s gangrene: 12-year experience from a tertiary care referral center. Turk J Neurol2019; 45(Supp. 1): S111–S116.
12.
Ruiz-TovarJCórdobaLDevesaJM.Prognostic factors in Fournier gangrene. Asian J Surg2012; 35(1): 37–41.
13.
MekiCSMangwiroTILazarusJ.Fournier’s gangrene: outcome analysis and prognostic factors. S Afr J Surg2018; 56(3): 43–46.
14.
El-QushayriAEKhalafKMDahyA, et al. Fournier’s gangrene mortality: a 17-year systematic review and meta-analysis. Int J Infect Dis2020; 92: 218–225.
15.
ChalyaPLIgengeJZMabulaJB, et al. Fournier’s gangrene at a tertiary health facility in northwestern Tanzania: a single centre experiences with 84 patients. BMC Res Notes2015; 8: 481.
16.
TenórioCELLimaSVCAlbuquerqueAVD, et al. Risk factors for mortality in Fournier’s gangrene in a general hospital: Use of simplified founier gangrene severe index score (SFGSI). Int Braz J Urol2018; 44(1): 95–101.
17.
LinTYChengIHOuCH, et al. Incorporating Simplified Fournier’s Gangrene Severity Index with early surgical intervention can maximize survival in high-risk Fournier’s gangrene patients. Int J Urol2019; 26(7): 737–743.
18.
IoannidisOKitsikostaLTatsisD, et al. Fournier’s gangrene: lessons learned from multimodal and multidisciplinary management of perineal necrotizing fasciitis. Front Surg2017; 4: 36.
19.
TosunYAkıncıOKüçükHF.Risk factors for mortality in Fournier’s gangrene of anorectal origin. Ulus Travma Acil Cerrahi Derg2022; 28(8): 1128–1133.
20.
AzmiYAAlkaffFFPurbaAKR, et al. Factors for In-hospital mortality in 145 male patients with Fournier’s gangrene: a 10-year observational study from a single tertiary referral center in Indonesia. Med Sci Monit2022; 28: e938578.
21.
AroraARegeSSurpamS, et al. Predicting mortality in Fournier gangrene and validating the Fournier Gangrene Severity Index: our experience with 50 patients in a tertiary care center in India. Urol Int2019; 102(3): 311–318.
22.
ErolBTuncelATokA, et al. Low magnesium levels an important new prognostic parameter can be overlooked in patients with Fournier’s gangrene: a multicentric study. Int Urol Nephrol2015; 47(12): 1939–1945.
23.
YangYWangLCYuXY, et al. How likely is septic shock to develop in a patient with Fournier’s gangrene? A risk prediction model based on a 7-year retrospective study. Gastroenterol Rep2022; 10: goac038.
24.
ZhangNYuXZhangK, et al. A retrospective case series of Fournier’s gangrene: necrotizing fasciitis in perineum and perianal region. BMC Surg2020; 20(1): 259.
MontriefTLongBKoyfmanA, et al. Fournier gangrene: a review for emergency clinicians. J Emerg Med2019; 57(4): 488–500.
27.
DoluoğluÖGKaragözMAKılınçMF, et al. Overview of different scoring systems in Fournier’s gangrene and assessment of prognostic factors. Turk J Urol2016; 42(3): 190–196.
28.
TrevelinSCCarlosDBerettaM, et al. Diabetes mellitus and sepsis: a challenging association. Shock2017; 47(3): 276–287.
29.
TranBAUpdikeWHBullersK, et al. Sodium–glucose cotransporter 2 inhibitor use associated with Fournier’s gangrene: a review of case reports and spontaneous post-marketing cases. Clin Diabetes2022; 40(1): 78–86.
30.
ZhouXYeXGuoX, et al. Safety of SGLT2 inhibitors: a pharmacovigilance study from 2013 to 2021 based on FAERS. Front Pharmacol2021; 12: 766125.
31.
Serrano OlaveABueno MoralAIMartínez BañónC, et al. Fournier’s gangrene under sodium-glucose cotransporter-2 inhibitors therapy in gynecological patients. Int J Environ Res Public Health2022; 19(10): 6261.
32.
IshigamiJMatsushitaK.Clinical epidemiology of infectious disease among patients with chronic kidney disease. Clin Exp Nephrol2019; 23(4): 437–447.
33.
SinghAAhmedKAydinA, et al. Fournier’s gangrene. A clinical review. Arch Ital Urol Androl2016; 88(3): 157–164.
34.
LauermanMHKolesnikOSethuramanK, et al. Less is more? Antibiotic duration and outcomes in Fournier’s gangrene. J Trauma Acute Care Surg2017; 83(3): 443–448.
35.
El-ShazlyMAzizMAboutalebH, et al. Management of equivocal (early) Fournier’s gangrene. Ther Adv Urol2016; 8(5): 297–301.
36.
ChenXHQinPPZhangZX, et al. A novel surgical debridement technique for the treatment of Fournier’s gangrene. Asian J Androl2021; 23(5): 541–542.
37.
SorensenMDKriegerJN.Fournier’s gangrene: epidemiology and outcomes in the general US population. Urol Int2016; 97(3): 249–259.
38.
OsbunNHampsonLAHoltSK, et al. Low-volume vs high-volume centers and management of Fournier’s gangrene in Washington State. J Am Coll Surg2017; 224(3): 270–275.e1.
39.
Insua-PereiraIFerreiraPCTeixeiraS, et al. Fournier’s gangrene: a review of reconstructive options. Cent Eur J Urol2020; 73(1): 74–79.
40.
DadaciMYildirimMECYararS, et al. Assessment of outcomes after Limberg flap reconstruction for scrotal defects in patients with Fournier’s gangrene. Wounds2021; 33(3): 65–69.
41.
TanBKRasheedMZWuWT.Scrotal reconstruction by testicular apposition and wrap-around skin grafting. J Plast Reconstr Aesthet Surg2011; 64(7): 944–948.
42.
OzkanOFKoksalNAltinliE, et al. Fournier’s gangrene current approaches. Int Wound J2016; 13(5): 713–716.
43.
JananeAHajjiFIsmailTO, et al. [Hyperbaric oxygen therapy adjunctive to surgical debridement in management of Fournier’s gangrene: Usefulness of a severity index score in predicting disease gravity and patient survival]. Actas Urol Esp2011; 35: 332–338.
44.
BonkatGBartolettiRBruyereF, et al. EAU guidelines on urological infections. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan, Italy 2023. EAU Guidelines Office, Arnhem, The Netherlands. http://uroweb.org/guidelines/compilations-of-all-guidelines/
45.
SchneidewindLAnheuserPSchönburgS, et al. Hyperbaric oxygenation in the treatment of Fournier’s gangrene: a systematic review. Urol Int2021; 105(3–4): 247–256.
46.
MindrupSRKealeyGPFallonB.Hyperbaric oxygen for the treatment of Fournier’s gangrene. J Urol2005; 173(6): 1975–1977.
47.
FeresOFeitosaMRRibeirodaRochaJJ, et al. Hyperbaric oxygen therapy decreases mortality due to Fournier’s gangrene: a retrospective comparative study. Med Gas Res2021; 11(1): 18–23.
48.
LiCZhouXLiuLF, et al. Hyperbaric oxygen therapy as an adjuvant therapy for comprehensive treatment of Fournier’s gangrene. Urol Int2015; 94(4): 453–458.
49.
RaizandhaMAHidayatullahFKlopingYP, et al. The role of hyperbaric oxygen therapy in Fournier’s gangrene: A systematic review and meta-analysis of observational studies. Int Braz J Urol2022; 48(5): 771–781.
50.
CretaMLongoNArcanioloD, et al. Hyperbaric oxygen therapy reduces mortality in patients with Fournier’s gangrene. Results from a multi-institutional observational study. Minerva Urol Nefrol2020; 72(2): 223–228.
51.
MichalczykŁGrabińskaABanaczykB, et al. Efficiency of hyperbaric oxygen therapy combined with negative-pressure wound therapy in the treatment strategy of Fournier’s gangrene -a retrospective study. Urol J2021; 19(4): 329–332.
52.
YanaralFBalciCOzgorF, et al. Comparison of conventional dressings and vacuum-assisted closure in the wound therapy of Fournier’s gangrene. Arch Ital Urol Androl2017; 89(3): 208–211.
53.
HaidariMNazerMRAhmadinejadM, et al. Honey in the treatment of Fournier’s gangrene as an adjuvant: a cross sectional study. J Pak Med Assoc2014; 64(5): 571–573.
54.
XuanWHeYHuangL, et al. Antimicrobial photodynamic inactivation mediated by tetracyclines in vitro and in vivo: photochemical mechanisms and potentiation by potassium iodide. Sci Rep2018; 8(1): 17130.
55.
PereiraNMFeitosaLSNavarroRS, et al. Use of photodynamic inactivation for in vitro reduction of prevalent bacteria in Fournier’s gangrene. Int Braz J Urol2018; 44(1): 150–155.
56.
SaifeeNHEvansHLMagaretAS, et al. Outcomes in necrotizing soft tissue infections treated with therapeutic plasma exchange. Transfusion2017; 57(6): 1407–1413.
